This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Background Health care systems are increasingly moving towards more integrated
approaches. Shared decision making (SDM) is central to these models but may be …

Poor adherence to statin therapy is linked to significantly increased risk of cardiovascular
events and death. Unfortunately, adherence to statins is far from optimal. This is an alarming …

Background: Coronary artery calcium (CAC) has been widely recognized as an important
predictor of cardiovascular disease (CVD). Given the finite resources, it is important to …

Familial hypercholesterolaemia (FH) is caused by a major genetic defect in the low-density
lipoprotein (LDL) clearance pathway. Characterised by LDL-cholesterol elevation from birth …

Purpose To examine HMG-CoA reductase inhibitor (statin) drug dispensing patterns to Nova
Scotia Seniors' Pharmacare program (NSSPP) beneficiaries over a 14-year period in …

Challenges with primary care access and overextended providers present opportunities for
pharmacists as patient care extenders for chronic disease management. The primary …

Objective The objective of our study was to explore the perspectives of patients and general
practitioners (GPs) regarding interventions to increase initiation of cholesterol lowering …

The main objective of this study is to gain knowledge about interactional factors that support
and obstruct mutual risk-assessments and shared decision-making (SDM) in clinical …